Epigenetic plasticity potentiates a rapid cyclical shift to and from an aggressive cancer phenotype

Int J Cancer. 2020 Jun 1;146(11):3065-3076. doi: 10.1002/ijc.32904. Epub 2020 Feb 22.

Abstract

Highly tumorigenic, drug-resistant cancer stem-like cells drive cancer progression. These aggressive cells can arise repeatedly from bulk tumor cells independently of mutational events, suggesting an epigenetic mechanism. To test this possibility, we studied bladder cancer cells as they cyclically shifted to and from a cancer stem-like phenotype, and we discovered that these two states exhibit distinct DNA methylation and chromatin accessibility. Most differential chromatin accessibility was independent of methylation and affected the expression of driver genes such as E2F3, a cell cycle regulator associated with aggressive bladder cancer. Cancer stem-like cells exhibited increased E2F3 promoter accessibility and increased E2F3 expression that drove cell migration, invasiveness and drug resistance. Epigenetic interference using a DNA methylation inhibitor blocked the transition to a cancer stem-like state and reduced E2F3 expression. Our findings indicate that epigenetic plasticity plays a key role in the transition to and from an aggressive, drug-resistant phenotype.

Keywords: E2F; cancer plasticity; cancer stem-like cells; chromatin accessibility; drug resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Cell Movement / genetics
  • Cell Plasticity / genetics*
  • Chromatin / metabolism
  • DNA Methylation / genetics*
  • Drug Resistance, Neoplasm / genetics
  • E2F3 Transcription Factor / genetics*
  • E2F3 Transcription Factor / metabolism
  • Gene Expression Regulation, Neoplastic / genetics
  • Humans
  • Neoplasm Invasiveness / genetics
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / pathology*
  • Promoter Regions, Genetic / genetics
  • Urinary Bladder Neoplasms / genetics*
  • Urinary Bladder Neoplasms / pathology

Substances

  • Chromatin
  • E2F3 Transcription Factor
  • E2F3 protein, human